Follow The Filings

TRLV Trulieve Cannabis

Trulieve Cannabis earnings company data as of 4:48 AM ET 10/7

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 6 Nov EPS 0.09 — —
Rev — — —

Insider trades

Open-market buys and sales by TRLV's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TRLV insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $14.7M sold by 1 insider under 10b5-1 plans
  1. Kim A. Rivers CEO
    Planned sale
    $1.2M 136,811 shares at $8.76 8.5% of stake
    Traded Jun 26 Filed Jun 26
  2. Kim A. Rivers CEO
    Planned sale
    $8.9M 1,080,000 shares at $8.27 40% of stake
    Traded Jun 23–25 Filed Jun 25
  3. Kim A. Rivers CEO
    Planned sale
    $4.5M 482,196 shares at $9.39 15% of stake
    Traded Jun 17–22 Filed Jun 22

Also filed in the last 12 months, not counted as buying or selling: 16 stock grants, 7 share withholdings for taxes, and 1 conversion.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
8-K 1.01,3.02,3.03,5.03,9.01
8-K 2.01,7.01,9.01
10-Q
8-K 5.07,9.01
SCHEDULE 13G —
8-K 5.02,9.01
DEF 14A
DEFA14A
8-K 5.02,9.01
8-K 5.07,9.01
8-K 8.01,9.01
8-K 1.01,2.01,9.01
8-K 2.02,7.01,9.01
10-Q
DEF 14A
DEFA14A
8-K 5.02
8-K 5.02,9.01
8-K 2.02,7.01,9.01
10-K
8-K 5.02
8-K 1.01,2.03,8.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.